|
|
| (41 intermediate revisions by 3 users not shown) |
| Line 79: |
Line 79: |
| ==References== | | ==References== |
| <references /> | | <references /> |
| The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>
| |
|
| |
|
| [[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]] | | [[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]] |
